LON:BPCR BioPharma Credit (BPCR) Share Price, News & Analysis GBX 0.87 +0.00 (+0.23%) As of 08/1/2025 12:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock About BioPharma Credit Stock (LON:BPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioPharma Credit alerts:Sign Up Key Stats Today's Range 0.86▼ 0.8750-Day Range 0.87▼ 0.9152-Week Range 0.80▼ 0.98Volume594,452 shsAverage Volume860,009 shsMarket Capitalization£1.03 billionP/E Ratio9.89Dividend Yield804.60%Price TargetN/AConsensus RatingN/A Company Overview BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom. Read More Receive BPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter. Email Address BPCR Stock News HeadlinesCash in on the biotech sector with specialist trust BioPharmaApril 3, 2025 | msn.comBioPharma Credit announces dividend payoutJanuary 23, 2025 | msn.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 2 at 2:00 AM | Banyan Hill Publishing (Ad)BioPharma Credit's (LON:BPCR) investors will be pleased with their respectable 43% return over the last five yearsJanuary 7, 2025 | finance.yahoo.comInvestors in BioPharma Credit (LON:BPCR) have seen respectable returns of 44% over the past five yearsJuly 31, 2024 | finance.yahoo.comBuy Rating Affirmed for Benitec Biopharma Following Promising BB-301 Trial Results and Financial BoostApril 22, 2024 | markets.businessinsider.comBioPharma Credit PLC (BPCP.L)February 26, 2024 | nz.finance.yahoo.comInvestors in BioPharma Credit (LON:BPCR) have seen notable returns of 40% over the past five yearsFebruary 22, 2024 | finance.yahoo.comSee More Headlines BPCR Stock Analysis - Frequently Asked Questions How have BPCR shares performed this year? BioPharma Credit's stock was trading at GBX 0.88 at the beginning of 2025. Since then, BPCR shares have decreased by 1.6% and is now trading at GBX 0.87. How do I buy shares of BioPharma Credit? Shares of BPCR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BioPharma Credit own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPharma Credit investors own include AFPO.L (AFPO), Altius Minerals (ATUSF), LiDCO Group Plc (LID.L) (LID), NexGen Energy (NXE), Peninsula Energy (PEN), Premier African Minerals (PREM) and 21512 (SAT.L) (SAT). Company Calendar Record date for 5/7 Dividend4/03/2025Ex-Dividend for 5/7 Dividend4/03/2025Dividend Payable5/07/2025Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:BPCR CIKN/A Webwww.bpcruk.com Phone44 13 9247 7500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 0.09 Trailing P/E Ratio9.89 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.42 billion Net Margins80.20% Pretax MarginN/A Return on Equity8.51% Return on Assets4.98% Debt Debt-to-Equity RatioN/A Current Ratio21.50 Quick Ratio14.07 Sales & Book Value Annual Sales£12.99 billion Price / Sales0.08 Cash FlowGBX 0.73 per share Price / Cash Flow1.19 Book ValueGBX 98.56 per share Price / Book0.01Miscellaneous Outstanding Shares118,721,336,824Free FloatN/AMarket Cap£1.03 billion OptionableNot Optionable Beta0.22 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:BPCR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
